{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:29:52Z","timestamp":1717115392230},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,30]]},"DOI":"10.7759\/cureus.61367","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T14:18:42Z","timestamp":1717078722000},"source":"Crossref","is-referenced-by-count":0,"title":["A Rare Case of Thoracic SMARCA4-Deficient Undifferentiated Tumor With Diffuse Brain Metastasis"],"prefix":"10.7759","author":[{"given":"Shui Ho","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei Alena M","family":"Dagat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naeem","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3399","article-title":"SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas","volume":"47","author":"Le Loarer F","year":"2015","unstructured":"Le Loarer F, Watson S, Pierron G, et al.. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet. 2015, 47:1200-5. 10.1038\/ng.3399","journal-title":"Nat Genet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00639-w","article-title":"Thoracic SMARCA4-deficient undifferentiated tumor","volume":"14","author":"Jiang J","year":"2023","unstructured":"Jiang J, Chen Z, Gong J, Han N, Lu H. Thoracic SMARCA4-deficient undifferentiated tumor. Discov Oncol. 2023, 14:51. 10.1007\/s12672-023-00639-w","journal-title":"Discov Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2021.06.001","article-title":"Recent updates in thoracic SMARCA4-deficient undifferentiated tumor","volume":"38","author":"Nambirajan A","year":"2021","unstructured":"Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. Semin Diagn Pathol. 2021, 38:83-9. 10.1053\/j.semdp.2021.06.001","journal-title":"Semin Diagn Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.61","article-title":"SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior","volume":"30","author":"Sauter JL","year":"2017","unstructured":"Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol. 2017, 30:1422-32. 10.1038\/modpathol.2017.61","journal-title":"Mod Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-1606","article-title":"SMARCA4-deficient non-small cell lung carcinoma: clinicodemographic, computed tomography, and positron emission tomography-computed tomography features","volume":"16","author":"Kim JH","year":"2024","unstructured":"Kim JH, Woo JH, Lim CY, An T, Han J, Chung MJ, Cha YK. SMARCA4-deficient non-small cell lung carcinoma: clinicodemographic, computed tomography, and positron emission tomography-computed tomography features. J Thorac Dis. 2024, 16:1753-64. 10.21037\/jtd-23-1606","journal-title":"J Thorac Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-019-06017-x","article-title":"Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients","volume":"29","author":"Cromb\u00e9 A","year":"2019","unstructured":"Cromb\u00e9 A, Alberti N, Villard N, Pilleul F, Buy X, Le Loarer F, Kind M. Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients. Eur Radiol. 2019, 29:4730-41. 10.1007\/s00330-019-06017-x","journal-title":"Eur Radiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13215","article-title":"Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report","volume":"10","author":"Takada K","year":"2019","unstructured":"Takada K, Sugita S, Murase K, et al.. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report. Thorac Cancer. 2019, 10:2312-5. 10.1111\/1759-7714.13215","journal-title":"Thorac Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063237","article-title":"Treatment of thoracic SMARCA4-deficient undifferentiated tumors: where we are and where we will go","volume":"25","author":"Longo V","year":"2024","unstructured":"Longo V, Catino A, Montrone M, et al.. Treatment of thoracic SMARCA4-deficient undifferentiated tumors: where we are and where we will go. Int J Mol Sci. 2024, 25:3237. 10.3390\/ijms25063237","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.11","article-title":"Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities","volume":"30","author":"Yoshida A","year":"2017","unstructured":"Yoshida A, Kobayashi E, Kubo T, et al.. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol. 2017, 30:797-809. 10.1038\/modpathol.2017.11","journal-title":"Mod Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.023","article-title":"SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas","volume":"15","author":"Rekhtman N","year":"2020","unstructured":"Rekhtman N, Montecalvo J, Chang JC, et al.. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020, 15:231-47. 10.1016\/j.jtho.2019.10.023","journal-title":"J Thorac Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-38490-6_8","article-title":"Differential diagnosis of intracranial masses","author":"Smirniotopoulos JG","year":"2020","unstructured":"Smirniotopoulos JG, J\u00e4ger HR. Differential diagnosis of intracranial masses. Diseases of the Brain, Head and Neck, Spine 2020-2023. Hodler J, Kubik-Huch RA, von Schulthess GK (ed): Springer, Cham, Switzerland; 2020. 93-104. 10.1007\/978-3-030-38490-6_8"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer - biology, biomarkers and therapy","volume":"17","author":"Mittal P","year":"2020","unstructured":"Mittal P, Roberts CW. The SWI\/SNF complex in cancer - biology, biomarkers and therapy. Nat Rev Clin Oncol. 2020, 17:435-48. 10.1038\/s41571-020-0357-3","journal-title":"Nat Rev Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.06.027","article-title":"Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI\/SNF complex members to pathogenesis","volume":"45","author":"Li L","year":"2014","unstructured":"Li L, Fan XS, Xia QY, et al.. Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI\/SNF complex members to pathogenesis. Hum Pathol. 2014, 45:2247-54. 10.1016\/j.humpath.2014.06.027","journal-title":"Hum Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100235","article-title":"Conversion surgery for advanced thoracic SMARCA4-deficient undifferentiated tumor with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin treatment: a case report","volume":"2","author":"Kunimasa K","year":"2021","unstructured":"Kunimasa K, Okami J, Takenaka S, et al.. Conversion surgery for advanced thoracic SMARCA4-deficient undifferentiated tumor with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin treatment: a case report. JTO Clin Res Rep. 2021, 2:100235. 10.1016\/j.jtocrr.2021.100235","journal-title":"JTO Clin Res Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2019.12.001","article-title":"SMARCA4-deficient thoracic tumors: a new entity (Article in French)","volume":"107","author":"Decroix E","year":"2020","unstructured":"Decroix E, Leroy K, Wislez M, Fournel L, Alifano M, Damotte D, Mansuet-Lupo A. SMARCA4-deficient thoracic tumors: a new entity (Article in French). Bull Cancer. 2020, 107:41-7. 10.1016\/j.bulcan.2019.12.001","journal-title":"Bull Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/23247096231176220","article-title":"Chemotherapy and immune checkpoint inhibitors in a case of SMARCA4-dUT: a case report and review of literature","volume":"11","author":"Pokhrel A","year":"2023","unstructured":"Pokhrel A, Yadav R, Manvar KK, Wu R, Jaswani V, Wasserman CB, Wang JC. Chemotherapy and immune checkpoint inhibitors in a case of SMARCA4-dUT: a case report and review of literature. J Investig Med High Impact Case Rep. 2023, 11:23247096231176220. 10.1177\/23247096231176220","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04806-y","article-title":"Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor","volume":"149","author":"Lin Y","year":"2023","unstructured":"Lin Y, Yu B, Sun H, et al.. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor. J Cancer Res Clin Oncol. 2023, 149:8663-71. 10.1007\/s00432-023-04806-y","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz160","article-title":"Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor","volume":"30","author":"Henon C","year":"2019","unstructured":"Henon C, Blay JY, Massard C, et al.. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. Ann Oncol. 2019, 30:1401-3. 10.1093\/annonc\/mdz160","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13070","article-title":"Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: a case report","volume":"10","author":"Naito T","year":"2019","unstructured":"Naito T, Umemura S, Nakamura H, et al.. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: a case report. Thorac Cancer. 2019, 10:1285-8. 10.1111\/1759-7714.13070","journal-title":"Thorac Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0142","article-title":"Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report","volume":"12","author":"Iijima Y","year":"2020","unstructured":"Iijima Y, Sakakibara R, Ishizuka M, et al.. Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. Immunotherapy. 2020, 12:563-9. 10.2217\/imt-2019-0142","journal-title":"Immunotherapy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/252498-a-rare-case-of-thoracic-smarca4-deficient-undifferentiated-tumor-with-diffuse-brain-metastasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T14:18:48Z","timestamp":1717078728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/252498-a-rare-case-of-thoracic-smarca4-deficient-undifferentiated-tumor-with-diffuse-brain-metastasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.61367","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}